# Structure Therapeutics Inc. (GPCR)

> Source: Nexqual · https://nexqual.com/GPCR · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Structure Therapeutics Inc. (GPCR), nexqual.com/GPCR" · informational, not investment advice.

**Price:** USD 21.94 (+2.14% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 21.48 · day 21.39–22.16 · 52w 20.5–94.9 · market cap $1.56B · NGM

## Key facts
- Analysts: Buy (mean 1.81 on a 1–5 scale) (16 analysts), mean target USD 107.29 (range 70–145).
- Total return with dividends: 1Y -33.3% vs S&P 500 +14.8%; 5Y -15.6% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05 (date not yet confirmed by the company), EPS estimate USD -0.24, revenue estimate $50.0M. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: GPCR paid no cash dividend in the last five years.
- Short interest: 13.72% of float (as of 2026-10-15), 4.8 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Operating income | -$52.6M | -$103M | -$158M | -$177M | -$258M |
| Net income | -$51.3M | -$89.6M | -$123M | -$141M | -$215M |
| EPS (diluted) | -$5.51 | -$0.81 | -$0.78 | -$0.80 | — |
| Free cash flow | -$46.3M | -$81.7M | -$118M | -$226M | -$225M |
| Cash + short-term investments | $90.8M | $467M | $884M | $1.45B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 1.2x · FCF yield -14.35% · Earnings yield -13.73%

## Analysts
Consensus Buy (mean 1.81 on a 1–5 scale), 16 analysts; mean target USD 107.29 (low 70, high 145).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Citizens | Reiterated | Market Outperform | $110 |
| 2026-08-07 | Citigroup | Target lowered | Buy | $100 → $97 |
| 2026-08-07 | Citizens | Target lowered | Market Outperform | $113 → $110 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2023-01-30) |
|---|---|---|
| Total return | -33.3% | -15.6% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | -33.5% | -4.4% |
| Volatility (annualized) | 93.0% | 86.6% |
| Max drawdown | -77.5% (Jan 2026→Oct 2026) | -78.4% (Oct 2023→Mar 2025) |

## Dividends
GPCR paid no cash dividend in the last five years.

## Short interest
7,147,328 shares sold short, 13.72% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 6,605,011 shares (+8.2%). Days to cover: 4.8 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/GPCR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name GPCR in their own reports (relationship from GPCR's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Schrodinger, Inc. (SDGR) | 10-K 2026-02-25 | "Our current collaborators include, but are not limited to, Ajax Therapeutics, Inc., BMS, Bright Angel Therapeutics Inc., Lilly, Novartis, Otsuka Pharmaceutical Co., Ltd., or Otsuka, Sanofi S.A., and S…" |

## Company outlook (8-K filed 2026-08-06)

- "Data are expected in Q3 2026. ·"
- "Data are expected in Q4 2026. ·"
- "Data are expected in Q4 2026. ·"
- "Data are expected in Q4 2026."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.24 | $-0.19 | −$0.05 | $50.0M | 10 |
| Next quarter (ends 2026-12-31) | $-0.49 | $-0.45 | −$0.04 | $0 | 10 |
| Current fiscal year (ends 2026-12-31) | $-1.62 | $-1.43 | −$0.19 | $41.7M | 11 |
| Next fiscal year (ends 2027-12-31) | $-2.19 | $-2.08 | −$0.11 | $45,450 | 9 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±18.4%; last 8 reports averaged ±5.6%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 92.5% | ±18.4% |
| 2026-12-18 | 50 | 100.4% | ±29.9% |
| 2027-01-15 | 78 | 90.6% | ±33.7% |
| 2027-04-16 | 169 | 80.8% | ±44.0% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | −$0.49 | −$0.38 | Miss −28.9% | +5.2% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.35 | −$0.31 | Miss −12.9% | -4.3% |
| Feb 26, 2026 | Quarter ended Dec 31, 2025 | $0.20 | −$0.37 | Beat +$0.57 | -5.3% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.37 | −$0.37 | In line | +2.0% |
| Aug 6, 2025 | — | — | — | — | -2.9% |
| May 8, 2025 | — | — | — | — | -3.9% |
| Feb 27, 2025 | — | — | — | — | +19.5% |
| Nov 13, 2024 | — | — | — | — | +1.9% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-09-08 | 8-K | Regulation FD disclosure; Other material event — “ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial Results On September 8, 2026, the Company reported positive topline data for ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), from the SAD portion of the Phase 1/2a clinical trial. The SAD portion evaluated the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamic (PD) effects of ACCG-2671 in 31 healthy adult participants without obesity. A wide range of doses were…” | https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/0001104659-26-105688-index.htm |
| 2026-08-06 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1888886/000110465926092057/0001104659-26-092057-index.htm |
| 2026-08-06 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/0001104659-26-092017-index.htm |
| 2026-08-06 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 13.2% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1888886/000031506626002142/0000315066-26-002142-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.